CeriBell (NASDAQ:CBLL) Trading Down 7.8% – Here’s Why

CeriBell, Inc. (NASDAQ:CBLL)’s stock price was down 7.8% during mid-day trading on Thursday . The company traded as low as $16.60 and last traded at $16.51. Approximately 242,264 shares changed hands during trading, a decline of 24% from the average daily volume of 319,536 shares. The stock had previously closed at $17.91.

Wall Street Analyst Weigh In

CBLL has been the subject of a number of recent analyst reports. Weiss Ratings downgraded CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. Finally, Canaccord Genuity Group lowered their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.20.

CeriBell Stock Down 8.1%

The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.35 and a current ratio of 10.44. The stock’s 50-day moving average price is $19.16 and its two-hundred day moving average price is $18.87. The stock has a market capitalization of $623.60 million, a PE ratio of -10.10 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The business had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. As a group, analysts expect that CeriBell, Inc. will post -1.44 EPS for the current fiscal year.

Insider Activity

In related news, VP David Foehr sold 4,560 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.80, for a total value of $81,168.00. Following the transaction, the vice president directly owned 17,550 shares of the company’s stock, valued at approximately $312,390. This represents a 20.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Josef Parvizi sold 16,714 shares of CeriBell stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $20.27, for a total value of $338,792.78. Following the completion of the sale, the director directly owned 722,652 shares of the company’s stock, valued at approximately $14,648,156.04. The trade was a 2.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 175,119 shares of company stock valued at $3,310,772 over the last ninety days. 20.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CeriBell

A number of hedge funds have recently bought and sold shares of the business. Strs Ohio bought a new position in CeriBell during the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd boosted its holdings in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CeriBell in the 3rd quarter worth approximately $33,000. CWM LLC increased its position in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.